Patient-derived CD133+ lung cancer spheroids displayed enhanced tumorigenicity in vivo, and immunohistochemical analysis revealed that the subsequent CD133-derived tumors reproduced a heterogeneous phenotype resembling that of the original patient tumor [250]. The gene discussed is PROM1; the disease is lung cancer.